Last updated: September 24, 2026
Immune globulin subcutaneous (human), 20% liquid is a high-value specialty biologic category used mainly for primary immunodeficiency diseases and selected secondary immunodeficiency conditions. The principal U.S. products are Hizentra, Cuvitru and Xembify. Growth is driven by patient conversion from intravenous immunoglobulin, home administration, expanded diagnosis and long-term replacement therapy.
The category has durable demand but faces pricing pressure, plasma-collection constraints, payer controls and competition from intravenous immunoglobulin, facilitated subcutaneous products and emerging immune globulin delivery technologies. Product-level revenue disclosure is limited because manufacturers often report immunoglobulin sales in broader business segments.
What products contain immune globulin subcutaneous (human), 20% liquid?
The primary products are:
| Product |
Active ingredient |
Concentration |
Sponsor or manufacturer |
Main U.S. indications |
| Hizentra |
Human normal immunoglobulin |
20% |
CSL Behring |
Primary immunodeficiency; chronic inflammatory demyelinating polyneuropathy |
| Cuvitru |
Human normal immunoglobulin |
20% |
Takeda |
Primary immunodeficiency |
| Xembify |
Human immunoglobulin |
20% |
Grifols |
Primary immunodeficiency |
| Gamunex-C |
Human immune globulin |
10% |
Grifols |
Intravenous and subcutaneous use, but not a 20% liquid product |
| HyQvia |
Immune globulin 10% with recombinant hyaluronidase |
10% immune globulin |
Takeda |
Facilitated subcutaneous administration |
Hizentra has the broadest commercial profile because its label includes both primary immunodeficiency and CIDP maintenance therapy. Cuvitru and Xembify compete primarily in immunoglobulin replacement therapy for primary immunodeficiency [1-3].
How large is the subcutaneous immunoglobulin market?
The subcutaneous immunoglobulin market is a subset of the broader global plasma-derived immunoglobulin market. Public market estimates vary because they differ in geographic scope, hospital versus specialty-pharmacy inclusion, and treatment of facilitated subcutaneous products.
The commercial market has four structural characteristics:
- Immunoglobulin is a chronic therapy, producing recurring revenue and relatively low treatment discontinuation.
- Supply depends on human plasma collection, fractionation capacity and manufacturing yields.
- Subcutaneous administration is gaining share against intravenous administration in suitable patients.
- Product-level pricing is high, but net revenue is reduced by rebates, specialty-pharmacy discounts and payer utilization management.
The broader immunoglobulin market is measured in the tens of billions of dollars globally. The subcutaneous segment is materially smaller but has grown faster than conventional intravenous immunoglobulin in many developed markets because it supports home treatment and reduces infusion-center dependence [4].
What is driving market growth?
Growth is concentrated in five areas:
- Greater diagnosis of primary immunodeficiency disorders.
- Conversion of stable intravenous patients to home-based subcutaneous treatment.
- Increased use of Hizentra for CIDP maintenance therapy.
- Expansion of specialty-pharmacy distribution.
- Preference for lower-volume, higher-concentration products.
The 20% concentration reduces infusion volume relative to 10% products. This can improve administration convenience, although dosing frequency, injection-site tolerability and patient training remain important adoption factors.
What is the financial trajectory for Hizentra, Cuvitru and Xembify?
Manufacturer disclosures indicate sustained expansion of immunoglobulin demand, but direct product comparisons require caution because companies report different geographic and accounting categories.
| Product |
Company disclosure pattern |
Financial trajectory |
| Hizentra |
CSL reports product and business performance within Behring and immunoglobulin-related disclosures |
Long-term growth supported by PID and CIDP use, home administration and international expansion |
| Cuvitru |
Takeda reports immunoglobulin products within its plasma-derived therapies portfolio |
Growth supported by immunoglobulin demand and specialty-care use; product-level figures are not consistently separated |
| Xembify |
Grifols reports immunoglobulin revenue within broader plasma-derived product categories |
Growth depends on commercial uptake, plasma supply and Grifols’ broader immunoglobulin portfolio |
CSL has identified immunoglobulin as a major growth platform and has invested in plasma collection, fractionation and manufacturing capacity. Takeda has also treated immunoglobulin as a core plasma-derived therapy, with Cuvitru and HyQvia positioned across conventional and facilitated subcutaneous administration. Grifols has maintained a large immunoglobulin franchise anchored by its plasma-collection network [5-7].
The financial profile is attractive because patients generally require ongoing treatment. Revenue is less dependent on one-time initiation than in acute biologic markets. Gross margins remain exposed to plasma-acquisition costs, labor, energy, quality-control requirements and capacity utilization.
How does immune globulin subcutaneous compare with intravenous immunoglobulin?
Subcutaneous immunoglobulin has a different economic profile from intravenous immunoglobulin.
| Attribute |
Subcutaneous 20% liquid |
Intravenous immunoglobulin |
| Administration |
Home or clinic; frequent smaller doses |
Usually clinic or infusion center; intermittent larger doses |
| Infusion volume |
Lower because of 20% concentration |
Varies by concentration, commonly 5% or 10% |
| Infrastructure |
Requires patient training and injection equipment |
Requires venous access and infusion monitoring |
| Site-of-care cost |
Often lower after transition to home treatment |
Higher when administered in hospital or office |
| Patient convenience |
Usually higher for suitable patients |
Less convenient for many chronic users |
| Key tolerability issue |
Local injection-site reactions |
Systemic infusion reactions, thrombosis and headache risks |
| Commercial risk |
Payer restrictions and self-administration barriers |
Infusion-center economics and hospital purchasing |
SCIG does not replace IVIG for every patient. Patients requiring rapid serum IgG increases, high-dose immunomodulation or close clinical supervision may remain on intravenous treatment. The competitive effect is therefore gradual conversion rather than complete substitution.
What FDA regulatory status applies to 20% subcutaneous immune globulin?
Hizentra, Cuvitru and Xembify are FDA-approved biologic products. They are plasma-derived human immunoglobulin products regulated under biologics requirements, including manufacturing controls, donor screening, viral reduction and lot-release controls [1-3].
The U.S. regulatory pathway differs from a conventional small-molecule generic. A follow-on manufacturer would generally pursue a 351(k) biosimilar pathway or a 351(a) biologics license application, depending on the product and development strategy.
The FDA’s Purple Book, rather than the Orange Book, is the primary reference for biologic reference products and biosimilar relationships. Because these products are biologics, the traditional Orange Book Paragraph IV framework does not apply in the same way as it does for small-molecule drugs [8].
What is the Orange Book and Purple Book status of these products?
The relevant regulatory distinction is:
- Orange Book: primarily small-molecule drug approvals and listed patents.
- Purple Book: biological products, reference products, biosimilar products and interchangeability information.
- Biologics Price Competition and Innovation Act: establishes the principal U.S. biosimilar pathway.
- Patent litigation: generally proceeds under the BPCIA patent-exchange and litigation framework rather than a standard Hatch-Waxman Paragraph IV case.
A conventional Paragraph IV certification against Hizentra, Cuvitru or Xembify should not be assumed. A biosimilar developer would need to evaluate reference-product exclusivity, manufacturing comparability, clinical requirements and BPCIA patent procedures.
What patents protect Hizentra, Cuvitru and Xembify?
The strongest protection for these products is usually the combination of biologic exclusivity, manufacturing know-how, regulatory complexity and supply infrastructure rather than a single composition-of-matter patent.
Relevant patent categories include:
Formulation patents
Potential formulation claims may cover:
- Immunoglobulin concentration.
- Stabilizers and excipients.
- pH ranges.
- Protein aggregation control.
- Storage conditions.
- Container and delivery-device compatibility.
A 20% liquid formulation can be commercially difficult to replicate even where broad composition claims are limited. Small changes in excipients, protein concentration or processing can affect aggregation, viscosity, shelf life and injection-site tolerability.
Manufacturing and purification patents
Manufacturing protection may cover:
- Plasma pooling.
- Fractionation.
- Chromatographic purification.
- Viral inactivation and removal.
- Stabilization and filtration.
- Filling and container closure.
- Batch consistency and release testing.
These rights may be less visible to investors than product patents but can create practical barriers for biosimilar developers.
Method-of-use patents
Method-of-use protection may cover:
- Immunoglobulin replacement in primary immunodeficiency.
- Maintenance therapy in CIDP.
- Dose-ranging schedules.
- Subcutaneous administration.
- Home self-administration.
- Patient-selection criteria.
Method patents may influence litigation and settlement negotiations, particularly where an approved indication has meaningful commercial value. They do not necessarily prevent a competitor from marketing a product for nonprotected uses if lawful labeling and prescribing controls support a restricted-label strategy.
When does exclusivity expire for 20% subcutaneous immunoglobulin?
There is no single category-wide expiration date. Each product has separate regulatory exclusivity, patent and regulatory-history considerations.
| Product |
Exclusivity issue |
Commercial implication |
| Hizentra |
Biologic exclusivity, formulation and manufacturing rights, method-of-use rights |
Biosimilar entry requires technical and regulatory development; direct substitution may be limited |
| Cuvitru |
Biologic exclusivity plus product and manufacturing IP |
Competitive entry depends on reference-product strategy and payer adoption |
| Xembify |
Biologic exclusivity plus formulation, process and commercial infrastructure |
Market share is vulnerable to stronger incumbent distribution and supply networks |
A biologic reference product may receive 12 years of reference-product exclusivity under U.S. law, subject to statutory timing rules and product-specific regulatory history [9]. Patent expiration dates must be assessed from issued claims and terminal disclaimers, not inferred from the approval date.
Which companies are challenging the market?
The competitive landscape includes:
- CSL Behring, with Hizentra.
- Takeda, with Cuvitru and HyQvia.
- Grifols, with Xembify and other immunoglobulin products.
- Kedrion Biopharma, with plasma-derived immunoglobulin products.
- Octapharma, with intravenous and subcutaneous immunoglobulin products in selected markets.
- China-based and regional plasma-product manufacturers.
- Potential biosimilar developers seeking to enter through the 351(k) pathway.
The main competitive threat is not limited to another 20% liquid product. It includes 10% SCIG, facilitated SCIG, IVIG, next-generation delivery systems and products that reduce administration frequency.
What patent litigation and settlement risks exist?
Publicly visible litigation risk is generally lower than in major small-molecule markets because the category has fewer conventional Paragraph IV disputes. The principal legal risks are:
- BPCIA patent litigation initiated before or after biosimilar launch.
- Patent challenges involving formulation or manufacturing claims.
- Trade-secret disputes involving plasma processing.
- Contract disputes with specialty pharmacies or distributors.
- Product-liability litigation involving thrombosis, hemolysis, infection risk or administration reactions.
- Antitrust and access disputes involving supply allocation or contracting.
A biosimilar launch could occur through several scenarios:
- Entry after negotiated patent resolution.
- Launch after invalidity or noninfringement findings.
- At-risk launch before all patent disputes are resolved.
- Limited-label entry that excludes protected indications.
- Delayed entry caused by manufacturing or FDA deficiencies rather than patent barriers.
What manufacturing barriers protect the market?
Plasma supply is the most important operational barrier. A competitor needs access to:
- Qualified plasma donors.
- Collection centers.
- Fractionation capacity.
- Viral-clearance validation.
- Specialized biologics manufacturing.
- Cold-chain distribution.
- Lot-release and pharmacovigilance systems.
- Commercial payer and specialty-pharmacy access.
This creates a higher entry threshold than for many injectable small molecules. Capacity additions also require years of capital investment, regulatory validation and operational qualification.
Plasma collection recovered from pandemic disruption, but the industry remains exposed to donor availability, collection productivity and geographic concentration. Manufacturers with integrated plasma networks have a cost and supply advantage over companies that rely heavily on third-party sourcing.
What generic or biosimilar entry risks exist?
The near-term risk is more likely to be gradual price erosion than an immediate generic-style collapse.
High-risk factors
- A well-funded biosimilar with a 20% liquid formulation.
- Demonstrated interchangeability or strong payer preference.
- A large plasma-collection network.
- Manufacturing scale sufficient to compete on supply and price.
- A narrow or manageable patent estate.
- Contracting with major specialty-pharmacy channels.
Lower-risk factors
- Complex manufacturing and comparability requirements.
- Limited plasma supply.
- Patient preference for established products.
- Training and device switching costs.
- Multiple indications with different dosing practices.
- Physician concern about switching stable patients.
Biosimilar substitution may be less automatic than small-molecule substitution because interchangeability, state pharmacy laws and payer policies can affect switching behavior.
How strong is the patent estate for this biologic category?
The effective protection is moderate to strong, but it is distributed across several layers.
| Protection layer |
Relative strength |
Reason |
| Regulatory exclusivity |
Moderate |
Time-limited and subject to statutory rules |
| Composition patents |
Variable |
Protein products can have narrower composition protection |
| Formulation patents |
Moderate |
Concentration, stabilizers and storage claims can be valuable |
| Manufacturing patents |
Strong in practice |
Process replication is technically difficult |
| Trade secrets |
Strong |
Process parameters and quality controls may not be publicly disclosed |
| Plasma supply |
Strong operational barrier |
Collection networks are expensive and slow to replicate |
| Brand and channel access |
Moderate |
Specialty-pharmacy relationships support retention |
The commercial moat is therefore broader than the issued patent list. A patent challenge could succeed while a biosimilar still faces manufacturing, supply and market-access obstacles.
What revenue exposure exists for manufacturers?
Immunoglobulin is material to the financial profiles of CSL, Takeda and Grifols.
CSL has substantial exposure through CSL Behring’s plasma-derived portfolio, with Hizentra positioned as a major specialty product. Takeda’s immunoglobulin franchise includes Cuvitru and HyQvia and is linked to the company’s plasma-derived therapies strategy. Grifols remains highly exposed to plasma collection and immunoglobulin economics across its portfolio [5-7].
Revenue sensitivity is driven by:
- Volume growth.
- Net price and payer mix.
- Plasma collection cost.
- Manufacturing utilization.
- Product mix between IVIG, SCIG and facilitated SCIG.
- Foreign-exchange movements.
- Regulatory supply interruptions.
- Patient conversion rates.
Because companies often disclose immunoglobulin sales by franchise rather than by brand, investors should avoid attributing total plasma-derived revenue to a single 20% SCIG product.
How does Hizentra compare with Cuvitru and Xembify?
Hizentra has the strongest disclosed strategic position because of its PID and CIDP indications and CSL’s global plasma infrastructure. Cuvitru competes with a high-concentration product backed by Takeda’s plasma-derived portfolio and is complemented by HyQvia’s facilitated administration model. Xembify benefits from Grifols’ plasma network but competes against larger established commercial franchises.
| Dimension |
Hizentra |
Cuvitru |
Xembify |
| Concentration |
20% |
20% |
20% |
| Core strength |
Broad clinical positioning and scale |
Takeda portfolio and delivery options |
Grifols plasma infrastructure |
| Main weakness |
Pricing and supply exposure |
Portfolio overlap with HyQvia |
Smaller commercial position than leading incumbents |
| Key growth lever |
CIDP and home treatment |
PID conversion and facilitated-SCIG cross-selling |
Expanded adoption and distribution |
| Main threat |
Biosimilar or payer-led switching |
Competing SCIG and HyQvia substitution |
Scale, contracting and physician familiarity |
Key Takeaways
- Immune globulin subcutaneous (human), 20% liquid is a recurring-revenue specialty biologic category.
- Hizentra, Cuvitru and Xembify are the principal U.S. 20% SCIG products.
- Market growth comes from diagnosis, IVIG-to-SCIG conversion, home administration and chronic CIDP treatment.
- The commercial moat depends on regulatory exclusivity, manufacturing know-how, plasma supply and specialty-pharmacy access.
- Traditional Hatch-Waxman Paragraph IV analysis is not the correct primary framework; Purple Book and BPCIA considerations are more relevant.
- Biosimilar risk is real but likely to produce gradual price and share pressure rather than an immediate generic-style disruption.
- Product-level revenue comparisons are constrained because manufacturers generally report immunoglobulin sales in broader business categories.
- Hizentra has the strongest commercial position based on indication breadth and CSL’s infrastructure, while Cuvitru and Xembify remain credible competitors.
FAQs
Is immune globulin subcutaneous 20% a biosimilar or a generic?
It is a biologic product derived from human plasma. A competing product would generally require a biologics license application or biosimilar application rather than a conventional abbreviated new drug application.
Which 20% SCIG product has the largest commercial advantage?
Hizentra has the strongest overall commercial position because it combines a 20% formulation, broad clinical use and CSL Behring’s plasma and specialty-pharmacy infrastructure.
Can patients automatically substitute one SCIG product for another?
No. Substitution depends on the product label, prescription, payer policy, state law, device requirements and clinical judgment. A patient may require new training or dose adjustment after switching.
Does the Orange Book list all patents for Hizentra, Cuvitru or Xembify?
No. The Orange Book is not the primary patent and exclusivity reference for these biologics. The Purple Book and public patent records are more relevant, although neither replaces a claim-by-claim patent analysis.
What is the largest long-term risk to SCIG revenue?
The largest structural risks are biosimilar competition, payer-driven price reductions, plasma-supply disruption and migration to delivery systems that reduce administration burden.
References
-
U.S. Food and Drug Administration. (2023). Hizentra prescribing information. CSL Behring LLC.
-
U.S. Food and Drug Administration. (2023). Cuvitru prescribing information. Takeda Pharmaceuticals U.S.A., Inc.
-
U.S. Food and Drug Administration. (2023). Xembify prescribing information. Grifols Therapeutics LLC.
-
Marketing Research Bureau. (2024). The plasma proteins market in the United States and worldwide.
-
CSL Limited. (2024). Annual report 2024.
-
Takeda Pharmaceutical Company Limited. (2024). Annual report 2024.
-
Grifols, S.A. (2024). Annual report 2023.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
-
Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.
